



# Modeling of viral kinetics in patients chronically infected with hepatitis B and D

Natalie Filmann, Tje Lin Chung, Eva Herrmann  
Institute of Biostatistics and Mathematical Modelling  
Goethe-University Frankfurt Main, Germany

June 9, 2009



## Introduction - Virus kinetic models

- The dynamics of a virus population in vivo could be described by a simple ODE (Bonhoeffer et al., 1997; Nowak and May, 2000)

$$\frac{dT}{dt} = \lambda - mT - \beta TV$$

$$\frac{dI}{dt} = \beta TV - \delta I$$

$$\frac{dV}{dt} = pI - cV$$




## Introduction - Virus kinetic models



- Models for HIV, HBV, HCV mono-infection are an important tool for
  - Understanding dynamics of several viruses diseases
  - Quantifying effectiveness of anti-viral therapy
  - Comparing and optimizing anti-viral therapy
- Now: Introducing HBV-HDV-Viral kinetic model


# Medical background - HBV

- Hepatitis B is a disease caused by HBV (hepatitis B virus) which infects the liver and causes an inflammation called hepatitis




# Medical background - HBV

- **HBsAg: Hepatitis B surface Antigen** 
  - Vast amount of HBsAg particles in blood serum
  - Produced in liver cells
  - HDV life-cycle relies on HbsAg
  - HDV uses HBsAg as surface protein
- **Anti-HBs: Hepatitis B surface antibody** 
  - Anti-HBs neutralizes HBsAg particles
  - Anti-HBs makes HBV noninfectious but cannot cure infected liver cells
- **HBIG: Hepatitis B immune globulin**
  - Blood plasma product administered after liver transplantation (LTX)
  - HBIG contains Anti-HBs and can prevent hepatitis B reinfection




# Medical background - HDV

- Delta hepatitis is the most severe form of chronic viral hepatitis
  - Frequently leading to end-stage liver disease and hepatocellular carcinoma
- Hepatitis D virus ● is a defective virus that is dependent for its life cycle on HBV-particles (HBsAg) ○
  - Therefore HDV-infection can only occur as coinfection or as superinfection with HBV-infection
  - Produced in liver cells which contain HBV and released to blood





# HBV-HDV-host-interaction




# Material and Methods

- The data: 25 coinfecting patients who underwent liver transplantation
- Measured was:
  - HB Virus load (qualitative)
  - HD Virus load
  - HbsAg-level
  - Anti-HBs-level after transplantation
  - HBIG dose after transplantation
- Measured once before LTX and every 1,2,3 days after LTX
  - Until HBsAg became negative  
(Range: 1-13 days, except one patient who didn't achieved negativity at all)




# Virus dynamics after Liver Transplantation

Median values – Anti HBs, HDV, HBsAG




# Virus dynamics after Liver Transplantation

Kinetics of HDV-RNA, HBsAg and anti-HBs in representative patients




# Virus dynamics after Liver Transplantation

Kinetics of HDV-RNA, HBsAg and anti-HBs in representative patients



# Virus dynamics after Liver Transplantation

Kinetics of HDV-RNA, HBsAg and anti-HBs in two representative patients





## Model after liver transplantation

- Assume clearing of HBsAg and HDV due to anti-HBs
- No reinfection of the liver

$$A = k_0 + (k_{\max} - k_0) \cdot (1 - \exp(-kt))$$

$$\frac{dV_D}{dt} = -A c_D V_D$$

$$\frac{dH}{dt} = -A c_H H$$

### Compartments

A: Anti - HBs

$V_D$ : Hepatitis D viremia

H: HBsAg

### Kinetic parameters

$c_D$ : Clearance of free HDV

$c_H$ : Clearance of free HBsAg


$k_0$ : Initial anti - HBs level

k: Rate of saturation

$k_{\max}$ : Maximal saturation




# Fitting results






# Fitting results






# Fitting results








# Fitting results





# Fitting results





## Results and Outline

- Overall similar kinetic pattern in HDV and HBsAg decline
  - Early HDV-RNA decline and HBsAg decline paralleled almost exactly in all 25 patients
- Nevertheless, two kinetic profiles were observed:
  - Most patients showed a relatively linear decrease (in logarithmic scale)
  - Some show a plateau phase in both, HBsAg and HDV DNA:
- Model modification to account for these profiles:
  - Directly model the single doses of HBIG in a PK-PD approach
  - Inclusion of possible time lags
  - Analyze if these plateaus can be explained by reinfection



# Outline - the full model

## Modelling virus-virus-host-interaction

$$\frac{dV_B}{dt} = p_B I_B - A c_B V_B + p_{DB} I_{DB}$$

$$\frac{dV_D}{dt} = p_D I_D - A c_D V_D$$

$$\frac{dI_B}{dt} = \beta_B T V_B - \delta_B I_B - \beta_D I_B V_D$$

$$\frac{dI_{DB}}{dt} = \beta_D I_B V_D - \delta_{DB} I_{DB}$$

$$\frac{dH}{dt} = p_H I_B - A c_H H + p_{HD} I_{DB}$$

$$A = k_0 + (k_{max} - k_0) \cdot (1 - \exp(-kt))$$

$$T = T_{max} - I_B$$

### Compartments

$V_B$  : Hepatitis B viremia  
 $V_D$  : Hepatitis D viremia  
 $I_B$  : Monoinfected cells  
 $I_{DB}$  : Coinfected cells  
 $T$  : Target cells  
 $T_{max}$  : Maximal contingent of target cells  
 $H$  : HBsAg  
 $A$  : Anti - HBs

### Kinetic parameters

$p_B$  : Viral production rate (free HBV)  
 $p_{DB}$  : Viral production rate (free HBV)  
 $p_D$  : Viral production rate (free HDV)  
 $p_H$  : HBsAg production rate (free HBsAg)  
 $p_{HD}$  : HBsAg production rate (free HBsAg)  
 $c_B$  : Clearance of free HBV  
 $c_D$  : Clearance of free HDV  
 $c_H$  : Clearance of free HBsAg  
 $\beta_B$  : De novo monoinfection rate  
 $\beta_D$  : De novo coinfection rate  
 $\delta_B$  : Monoinfected cell loss rate  
 $\delta_{DB}$  : Coinfected cell loss rate  
 $k$  : Treatment effect due to HBIG administration



## Conclusions and Outline

- It seems as if HDV fully parallels HbsAg kinetics without differences in degradation rates
- The dynamics does not yet indicate reinfection but this has to be analyzed with more detailed data
- Modeling the observed plateau phase by introducing time lags
  - Considering time lags - using the full model
  - Introduce pharmacokinetics (HBIG) as well
- Modeling approach may help to individualize HBIG dosing schemes in patients undergoing HBV/HDV-indicated or HBV-indicated liver transplantation
  - Up to now HBIG is given at a fixed dose until HBsAG level is negative



## References

- Roseneau J, Kreutz T, Kujawa M, et al.: HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. *Journal of Hepatology* 2007, 46: 635-644.
- Dahari et al.: Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. *Journal of Hepatology*, 2005, 42:491-498.
- Powers et al.: Kinetics of Hepatitis C virus Reinfection After Liver Transplantation. *Liver Transplantation* 2006, 12:207-216.



Thank you for your attention.